Acute rhabdomyolysis as a complication of interferon treatment for stage IIIc melanoma.
Interferon alfa-2b is a treatment option for select patients with stage 3 melanoma. To highlight the potential complication of acute rhabdomyolysis from interferon alfa-2b in this patient population. We present a case of a 63-year-old female with stage IIIc melanoma who developed acute rhabdomyolysis after completing 2 of 4 weeks of induction with high-dose interferon alfa-2b. She recovered after hydration with intravenous fluids and discontinuation of interferon alfa-2b. Review of the literature revealed eight cases of reported rhabdomyolysis triggered by interferon use, including four cases of melanoma. In patients treated with interferon, especially at high doses, screening for creatine kinase and myoglobinuria should be performed if the patient develops symptoms suggestive of acute rhabdomyolysis.